Skip to content
MEDP

Medpace Holdings, Inc.

Medpace Holdings, Inc. Q1 FY2026 earnings call

April 23, 2026 · fiscal period ended 2026-03

EPS · actual vs est

$4.28 / $3.74Beat +14.4%

Revenue · actual vs est

$706.6M / $697.6MBeat +1.3%
Ask about this call

Summary

Generated 2026-04-23

Management highlights

Key managerial messages include acknowledging Jesse Geiger's 18.5 years of service, discussing Q1 results with cancellations, net bookings, RFPs, strong initial reward notifications and win rate, EBITDA and net income figures, customer concentration, cash flow from operating activity, and net day sales outstanding.

View in transcript ↓

Segment performance

Revenue for the first quarter of 2026 was $706.6 million, representing a year-over-year increase of 26.5%. EBITDA was $149.4 million, up 25.9% compared to the prior year. Net income was $123.9 million, up 8.1% compared to the prior year period. Ending backlog as of March 31st, 2026 was approximately $2.9 billion, an increase of 2.9% from the prior year, with approximately $1.94 billion of backlog projected to convert to revenue in the next 12 months.

View in transcript ↓

Guidance

2026 guidance ranges for revenue, EBITDA, net income, and EPS are unchanged from the prior quarter based on an effective tax rate of 19 to 20% and interest income of $27.5 million. There are no additional share purchases in the guidance.

View in transcript ↓

Risks

Discussions on cancellations being a factor, impact of M&A on ongoing work, variability in RFP trends, AI investment needing significant outlay before net benefit, and potential risks from backlog conversion issues.

View in transcript ↓

Q&A highlights

First question from Max Muck on cancellations dynamics, August's response; David Windley's question on metabolic cancellations and GLP-1 exposure, August's response; Anne Hines' question on gross bookings and M&A exposure, responses; Charles Reilly's questions on cancellations mix and pass-through revenues; Eric Coldwell's questions on book-to-bill and backlog decline; Jalendra Singh's questions on RFP trends and AI impact; Luke Sergat's question on large pharma focus; Sean Dodge's question on win rate initiatives and headcount; Michael Attorney's question on AI commercial usage; Ryan Halstead's questions on SG&A and cancellations restart; Eric Oldwell's questions on book-to-bill and pre-backlog; Justin Bowers' questions on gross vs net bookings and award recognition; David Windley's follow-up questions on award to booking cadence and commitment to the company

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$4.28$3.74+14.4%
Revenue$706.6M$697.6M+1.3%

Transcript

April 23, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.